Four additional rounds (rounds 6b to 9b) were performed to adopt the cell-SELEX protocol for use with MCF-7 cells, a human breast cancer cell line known to overexpress TROP2 [42] (Figure S4). This evidence concerns the gene TACSTD2 and breast cancer.